Literature DB >> 23526073

Characterization of β-galactosidase isoforms from Bacillus circulans and their contribution to GOS production.

Anja Warmerdam1, Ekaraj Paudel, Wanqing Jia, Remko M Boom, Anja E M Janssen.   

Abstract

A β-galactosidase preparation from Bacillus circulans consists of four isoforms called β-gal-A, β-gal-B, β-gal-C, and β-gal-D. These isoforms differ in lactose hydrolysis and galacto-oligosaccharide (GOS) synthesis at low substrate concentrations. For this reason, using a selection of the isoforms may be relevant for GOS production, which is typically done at high substrate concentrations. At initial lactose concentrations in between 0.44 % and 0.68 % (w/w), β-gal-A showed the least oligosaccharide formation, followed by β-gal-B and β-gal-C; most oligosaccharides were formed by β-gal-D. The differences in behavior were confirmed by studying the thermodynamics of lactose conversion with isothermal titration calorimetry since especially β-gal-A showed a different profile than the other isoforms. Also during the conversion of allolactose and 4-galactosyllactose at 0.44 % and 0.61 % (w/w), respectively, β-gal-A and β-gal-D showed clear differences. In contrast to above findings, the selectivity of the isoforms did hardly differ at an initial lactose concentration of 30 % (w/w), except for a slightly higher production of galactose with β-gal-A. These differences were hypothesized to be related to the different accessibility of the active sites of the isoforms for different-sized reactants. The initial GOS formation rates of the isoforms indicate that β-gal-A and β-gal-B are the best isoforms for GOS production at high lactose concentrations.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23526073     DOI: 10.1007/s12010-013-0181-7

Source DB:  PubMed          Journal:  Appl Biochem Biotechnol        ISSN: 0273-2289            Impact factor:   2.926


  8 in total

Review 1.  Harnessing glycoenzyme engineering for synthesis of bioactive oligosaccharides.

Authors:  Mounir Benkoulouche; Régis Fauré; Magali Remaud-Siméon; Claire Moulis; Isabelle André
Journal:  Interface Focus       Date:  2019-02-15       Impact factor: 3.906

Review 2.  Synthesis and purification of galacto-oligosaccharides: state of the art.

Authors:  Carlos Vera; Andrés Córdova; Carla Aburto; Cecilia Guerrero; Sebastián Suárez; Andrés Illanes
Journal:  World J Microbiol Biotechnol       Date:  2016-10-18       Impact factor: 3.312

3.  β-galactosidase stability at high substrate concentrations.

Authors:  Anja Warmerdam; Remko M Boom; Anja Em Janssen
Journal:  Springerplus       Date:  2013-08-27

4.  Biochemical characterization of mutants in the active site residues of the β-galactosidase enzyme of Bacillus circulans ATCC 31382.

Authors:  Jelle B Bultema; Bas J H Kuipers; Lubbert Dijkhuizen
Journal:  FEBS Open Bio       Date:  2014-11-12       Impact factor: 2.693

5.  Analysis of Domain Architecture and Phylogenetics of Family 2 Glycoside Hydrolases (GH2).

Authors:  David Talens-Perales; Anna Górska; Daniel H Huson; Julio Polaina; Julia Marín-Navarro
Journal:  PLoS One       Date:  2016-12-08       Impact factor: 3.240

6.  Biochemical Characterization of the Functional Roles of Residues in the Active Site of the β-Galactosidase from Bacillus circulans ATCC 31382.

Authors:  Huifang Yin; Tjaard Pijning; Xiangfeng Meng; Lubbert Dijkhuizen; Sander S van Leeuwen
Journal:  Biochemistry       Date:  2017-06-05       Impact factor: 3.162

7.  Engineered Glycosidases for the Synthesis of Analogs of Human Milk Oligosaccharides.

Authors:  Pavlína Nekvasilová; Michaela Hovorková; Zuzana Mészáros; Lucie Petrásková; Helena Pelantová; Vladimír Křen; Kristýna Slámová; Pavla Bojarová
Journal:  Int J Mol Sci       Date:  2022-04-07       Impact factor: 6.208

8.  A New β-Galactosidase from the Antarctic Bacterium Alteromonas sp. ANT48 and Its Potential in Formation of Prebiotic Galacto-Oligosaccharides.

Authors:  Shangyong Li; Xiangjie Zhu; Mengxin Xing
Journal:  Mar Drugs       Date:  2019-10-23       Impact factor: 5.118

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.